CA2440190A1 - Compositions de levothyroxine et procedes associes - Google Patents

Compositions de levothyroxine et procedes associes Download PDF

Info

Publication number
CA2440190A1
CA2440190A1 CA002440190A CA2440190A CA2440190A1 CA 2440190 A1 CA2440190 A1 CA 2440190A1 CA 002440190 A CA002440190 A CA 002440190A CA 2440190 A CA2440190 A CA 2440190A CA 2440190 A1 CA2440190 A1 CA 2440190A1
Authority
CA
Canada
Prior art keywords
composition
levothyroxine
tablet
standard
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002440190A
Other languages
English (en)
Inventor
G. Andrew Franz
Elaine A. Strauss
Philip A. Dimenna
Rocco L. Gemma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Publication of CA2440190A1 publication Critical patent/CA2440190A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

L'invention concerne d'une manière générale des compositions pharmaceutiques stables et des procédés de fabrication et d'administration de celles-ci. Dans un mode de réalisation, l'invention concerne des compositions pharmaceutiques stabilisées renfermant des principes actifs sur le plan pharmaceutique, tels que la lévothyroxine (T4) sodique et la liothyronine (T3) sodique (médicaments à base d'hormone thyroïdienne), de préférence sous une forme galénique solide à libération immédiate. L'invention concerne également des procédés de fabrication et d'utilisation de ces compositions à libération immédiate et stabilisées.
CA002440190A 2001-02-15 2002-02-15 Compositions de levothyroxine et procedes associes Abandoned CA2440190A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/268,998 2001-02-15
US60/269,009 2001-02-15
PCT/US2002/004665 WO2003070217A1 (fr) 2002-02-15 2002-02-15 Compositions de levothyroxine et procedes associes

Publications (1)

Publication Number Publication Date
CA2440190A1 true CA2440190A1 (fr) 2003-08-28

Family

ID=27752550

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002440190A Abandoned CA2440190A1 (fr) 2001-02-15 2002-02-15 Compositions de levothyroxine et procedes associes

Country Status (4)

Country Link
EP (1) EP1474103A1 (fr)
JP (1) JP2005517720A (fr)
CA (1) CA2440190A1 (fr)
WO (1) WO2003070217A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
CA2587805C (fr) * 2007-04-25 2014-02-18 The Procter & Gamble Company Uniformite amelioree de contenu de vitamine d dans des formes dosifiees pharmaceutiques
CN109010295A (zh) * 2018-08-29 2018-12-18 北京兴源联合医药科技有限公司 一种左甲状腺素钠冻干口腔崩解片

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine

Also Published As

Publication number Publication date
WO2003070217A1 (fr) 2003-08-28
JP2005517720A (ja) 2005-06-16
EP1474103A1 (fr) 2004-11-10

Similar Documents

Publication Publication Date Title
US6555581B1 (en) Levothyroxine compositions and methods
JP2020063292A (ja) ランタン化合物を含むカプセル製剤及び粉末製剤
US20040202716A1 (en) Composition
US20080003284A1 (en) Levothyroxine compositions and methos
US20030195253A1 (en) Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7101569B2 (en) Methods of administering levothyroxine pharmaceutical compositions
US7067148B2 (en) Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
WO2003028624A2 (fr) Compositions de levothyroxine et procedes
CA2440190A1 (fr) Compositions de levothyroxine et procedes associes
US20030199585A1 (en) Levothyroxine compositions and methods
US20030180353A1 (en) Stabilized pharmaceutical compositions
US20030194437A1 (en) Levothyroxine compositions having unique triiodothyronine Cmax properties
US20030180356A1 (en) Levothyroxine compositions having unique triiodothyronine Tmax properties
WO2003013441A2 (fr) Compositions de levothyroxine et procedes connexes
WO2004014318A2 (fr) Compositions de levothyroxine et procedes
US20030199588A1 (en) Levothyroxine compositions and methods
US20030185885A1 (en) Non-granulated levothyroxine pharmaceutical compositions
US20030198672A1 (en) Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030198667A1 (en) Methods of producing dispersible pharmaceutical compositions
US20030198671A1 (en) Levothyroxine compositions having unique plasma AUC properties
US20030203967A1 (en) Levothyroxine compositions having unique Tmax properties
US20030195254A1 (en) Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030190349A1 (en) Methods of stabilizing pharmaceutical compositions
US20030199587A1 (en) Levothyroxine compositions having unique Cmax properties
US20030194436A1 (en) Immediate release pharmaceutical compositions

Legal Events

Date Code Title Description
FZDE Dead